posted on 2019-02-22, 13:06authored byA Erzurumluoglu, C Batini, M Tobin, C Melbourne, D Brazel, Y Jiang, JM Hughey, V Turcot, X Zhan, et al
BACKGROUND: Smoking and alcohol use have been associated with common genetic variants in multiple loci. Rare
variants within these loci hold promise in the identification of biological mechanisms in substance use. Exome arrays
and genotype imputation can now efficiently genotype rare nonsynonymous and loss of function variants. Such
variants are expected to have deleterious functional consequences and to contribute to disease risk.
METHODS: We analyzed w250,000 rare variants from 16 independent studies genotyped with exome arrays and
augmented this dataset with imputed data from the UK Biobank. Associations were tested for five phenotypes:
cigarettes per day, pack-years, smoking initiation, age of smoking initiation, and alcoholic drinks per week. We
conducted stratified heritability analyses, single-variant tests, and gene-based burden tests of nonsynonymous/
loss-of-function coding variants. We performed a novel fine-mapping analysis to winnow the number of putative
causal variants within associated loci.
RESULTS: Meta-analytic sample sizes ranged from 152,348 to 433,216, depending on the phenotype. Rare coding
variation explained 1.1% to 2.2% of phenotypic variance, reflecting 11% to 18% of the total single nucleotide
polymorphism heritability of these phenotypes. We identified 171 genome-wide associated loci across all
phenotypes. Fine mapping identified putative causal variants with double base-pair resolution at 24 of these loci,
and between three and 10 variants for 65 loci. Twenty loci contained rare coding variants in the 95% credible
intervals.
CONCLUSIONS: Rare coding variation significantly contributes to the heritability of smoking and alcohol use. Finemapping genome-wide association study loci identifies specific variants contributing to the biological etiology of
substance use behavior.
Funding
This research has been conducted using the UK Biobank Resource under Application Number 16651. This work was supported by the National Institute on Drug Abuse and the National Human Genome Research Institute of the National Institutes of Health Grant Nos. R01DA037904 (to SIV), R21DA040177 (to DJL), R01HG008983 (to DJL), R01GM126479 (to DJL), and 5T32DA017637-13 (to DMB); funding sources listed in the Supplementary Note; and a National Science Foundation Graduate Research Fellowship (to JMH). This material is based on work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE1255832 (to JMH).
History
Citation
Biological Psychiatry, 2018, in press
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences
The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.